NOV 08, 2020 7:30 AM PST

Psychedelic Mushrooms Effectively Treat Major Depression

WRITTEN BY: Annie Lennon

image

Over 17 million people in the US and 300 million people worldwide are estimated to have experienced major depression. Now, researchers from Johns Hopkins University have found that two doses of psilocybin, the psychoactive ingredient in ‘magic mushrooms’, coupled with psychotherapy, can significantly reduce depressive symptoms. 

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” says Alan Davis, assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. 

“Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials.”

For the study, the researchers involved 24 people with a long-term history of depression, most of whom experienced persistent depressive symptoms for around two years prior to enrolling in the study. The average age of the participants was 39, while 16 were women, and 22 considered themselves as ‘white’. 

The treatment consisted of two psilocybin sessions lasting five hours each monitored by two clinicians taken two weeks apart between August 2017 and April 2019. Prior to the treatment and at one week and 4-week follow-ups from treatment completion, participants were assessed with a standard depression assessment tool known as the GRID-Hamilton Depression Rating Scale. 

All in all, 67% of participants showed more than a 50% reduction in depressive symptoms at a one-week follow-up. At the four-week follow-up, this number increased to 71% of participants. On top of this, at the four-week follow-up, 54% of participants no longer qualified for being depressed.

The researchers now say that they will follow the participants for another year to see how long the antidepressant effects of psilocybin-assisted psychotherapy last, and will report their results in a later publication. 

 

Sources: Neuroscience NewsNPR

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
NOV 26, 2020
Cannabis Sciences
Women More Likely than Men to Swap Prescription Medication for Cannabis
NOV 26, 2020
Women More Likely than Men to Swap Prescription Medication for Cannabis
The stigma around cannabis usage is fading as cannabis laws become increasingly lax. Now, researchers from DePaul Univer ...
DEC 09, 2020
Technology
AI Helps Drug Combination Therapy in Cancer
DEC 09, 2020
AI Helps Drug Combination Therapy in Cancer
Healthcare providers opt to multiple of therapies for cancer patients—often containing combo drugs. Research has s ...
DEC 15, 2020
Drug Discovery & Development
Drug Reverses Age-Related Mental Decline
DEC 15, 2020
Drug Reverses Age-Related Mental Decline
An experimental drug, called ISRIB, has shown to reverse age-related mental decline in mice with just a few doses " ...
DEC 30, 2020
Cannabis Sciences
Cannabis Reduces Stress and Anxiety in Over 95% of Cases
DEC 30, 2020
Cannabis Reduces Stress and Anxiety in Over 95% of Cases
Whether cannabis will induce feelings of relaxation or anxiety often feels like a coin toss. Now, however, researchers f ...
FEB 10, 2021
Drug Discovery & Development
Ketamine Reduces Suicidal Thoughts in Patients with Depression
FEB 10, 2021
Ketamine Reduces Suicidal Thoughts in Patients with Depression
Ketamine has been known for some time for its ability to tackle depression. Now, however, researchers have found that or ...
FEB 26, 2021
Microbiology
Good Bacteria Fights Bad Bacteria in a Clinical Trial
FEB 26, 2021
Good Bacteria Fights Bad Bacteria in a Clinical Trial
Eczema is a skin condition that causes a chronic, itchy rash. The most common form of the disorder, atopic dermatitis, i ...
Loading Comments...